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Cancer imaging
Radiology requires a mass of tissue, displacing tissue, infil-
trating tissue, for contrast. Nuclear Medicine does not require
a mass. It exploits the subtle differences between the cancer cell
and the normal cell for identification. There is also an amplifica-
tion factor. For example, antigen expression may be 500–50,000
per cell and receptor expression may be between 500 and 10,000
per cell. There is an affinity factor, antigen binding to antibody of
the order of 109 and receptor binding between 1010 –14 L/mol. There
is also the residence time so that which binds stays. These are
the bases of cancer imaging with Nuclear Medicine. Tumour de-
tection as a result of this amplification process means that a ra-
dioactive pinhead is detectable if it has enough activity on it. For
tumours less than 1.5 cm in diameter, size is not the determinant
of detection.
There are two directions for cancer imaging in Nuclear Medi-
cine: one, which may be termed the ‘Catch-All’, is to have increas-
ingly sensitive but non-specific (or only context-specific) agents
such as the bone scan, gallium-67 and Positron Emission To-
mography with F-18 DG. These react with inflammation, granulo-
ma and infection as well as tumours. The other is the ‘Catch-One’
approach to make an agent as specific and sensitive as possible.
There are agents which bind the tumours rather than inflammato-
ry tissue, such as Thallium 201, Tc-99m MIBI and In-111 Octreotide.
There are agents that are class-specific, such as I-123 MIBG, bind-
ing to neuro-endocrine tumours. There are those that are type-
specific, for example an antibody against lymphoma will only bind
to lymphoma and not other cancers and that used for colorectal
cancer, called Tc-99m PR1A3 (Cancer Research UK), which only
binds to colorectal cancer. It is in both murine and humanised form.
Radioimmunoscintigraphy
The requirements for radioimmunoscintigraphy are:
1. An antigen as specific as possible to the cancer.
2. A monoclonal antibody against the antigen.
3. The best radiolabel, which is usually Tc-99m.
4. A radiolabelling method that preserves binding efficiency.
5. An optimal imaging system and image data analysis.
There are many antibodies available for particular cancers
(Table 1).
The rules of radioimmunoscintigraphy are quite straightforward:
1. Specific antibody uptake increases with time. An image at 5–
–10 minutes after injection provides a tumour-free template
with which later images can be compared.
2. Non-specific uptake after the initial distribution decreases with
time as the level of the antibody falls in the blood.
3. The higher the count rate, the better the detection.
Cancer imaging of lymph nodes with radiolabelled monoclonal
antibodies, peptides or FDG PET allows one to overcome a prob-
lem with radiology of calling a 1 cm or smaller node „normal”. In
order to enlarge a lymph node beyond 1 cm in diameter, the can-
cer must have been present in a previously normal-sized node
and such cancers can be detected using these techniques.
Table 1. Radioimmunoscintigraphy in malignant disease
Colorectal cancer Anti CEA, B72-3, PR1A3, huPR1A3
Breast cancer and HMFG1, HMFG2, huHMFG1, SM3,
    ovarian cancer B72.3
Prostate cancer Anti PSMA, In-111 Prostascint,
Tc-99m MUJ 591
Melanoma 225-225 anti high molecular weight
melanoma antigen Tc-99m (Fab)2
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2. Where is the disease when PSA is rising and the bone scan
and radiology are normal?
3. What is the significance of PSA that is not zero but rising with-
in the normal range after radical prostatectomy or radical ra-
diotherapy?
FDG has low uptake in prostate cancer and is unreliable. It is
only of benefit in highly malignant spreading prostate cancer and
does not answer these questions. However they can be answered
by using radiolabelled monoclonal antibodies. These react with
a Prostate Specific Membrane Antigen, PSMA, which has an in-
tra-cellular domain against which Prostascint (In-111 CYT 356)
and the Technetium-99m labelled equivalent labelled in our de-
partment [4]. There is an extra cellular antigen domain against
which the antibody MUJ 591 reacts. This is labelled with I-131 in
the USA [5] and with Technetium-99m in our laboratory [6]. Using
the Technetium-99m agent the protocol is imaging at 10 minutes
and 24 hours. Using the Indium-111 agent the imaging is at 10
minutes, 24 and 48 hours, reviewed by Britton et al. [7].
A new protocol has been developed in this department using
double radionuclide energy imaging. On Day 1 a bone SPET 3
hours post-injection of Tc-99m MDP is made as well as the con-
ventional planar images and simultaneously a pelvic SPET one
hour post-injection of Indium-111 CYT 356 using the two energy
double radionuclide approach. This allows direct co-location of
the two images. On day 3 a blood pool image SPET 10 minutes
post-injection of pyrophosphate followed by Tc-99m, with simul-
taneous pelvic SPET for Tc-99m and Indium-111 Prostascint. The
images are then displayed. The bone scan image allows co-loca-
tion of the prostate images with anatomical features, and the blood
pool image allows the differentiation of involved lymph nodes from
tortuous blood vessels that occur in old men with prostate can-
cer. This technique has been refined with the G E Hawkeye Sys-
tem, which adds a CT scan with the same equipment for direct
co-location. The CT scan is of moderate quality but allows co-
location with a high resolution CT or MRI study if that is also per-
formed on the patient. With this new protocol the accuracy of Pros-
tascint studies is increased from 70–80% as reported to over 90%
in a preliminary evaluation.
Radionuclide receptor imaging
A receptor accepts a chemical agent such as a hormone,
a neurotransmitter, a cytokine or other biologically active peptides.
The binding process initiates a series of reactions within the cell
so that information is moved chemically from the cell surface to
the nucleus. This process is called signal transduction. Thus it is
that although the nucleus controls the cell, it is the cell environ-
ment that controls the nucleus through signal transduction from
receptor to nucleus. For Nuclear Medicine then one should image
the receptor or the altered receptor in the cancer cell. There are
over 100 biologically active peptides involved in cancer and nu-
clear medicine is only using about a dozen, of which only four are
commercially available.
The concept of receptor binding of a molecule is essentially
the action or interaction of a binder and a bindee. This relation-
ship is true for hormones and their receptors, enzymes and their
substrates, antigens and their antibodies and biologically active
agents and their binding sites. What is required for tissue charac-
Radiotherapy planning is conventionally done from images on
X-ray CT and recurrences tend to occur at the centre of the tumour,
where radio-resistant anoxic cells occur. Conformational planning
however becomes closer and closer to the 3D mass shown on CT
scanning. It may be predicted that recurrences will start to appear
at the tumour edge, because the biological extent of the cancer
exceeds the physical extent, as can be demonstrated by radioim-
munoscintigraphy, radiopeptide imaging and by FDG PET.
Axillary node involvement in breast cancer
As the breast-screening programme brings in more women
with small breast cancers, is axillary clearance still appropriate?
Up to 50% of women with operable breast cancer have an „un-
necessary” axillary clearance with associated morbidity in that the
histology shows no cancer in the nodes.  In order to image breast
cancer with monoclonal antibodies, serial imaging is essential with
an early image at 5–10 minutes to provide the template of a nor-
mal study. Imaging may also be undertaken at 5 hours but must
be undertaken at 22–24 hours. The late image is then compared,
using a change detection analysis technique, also called kinetic
analysis with probability mapping. The matrix of 5 × 5 pixels is
made and the middle pixel is centred on each of the pixels of the
early and late image. In this way one is able to compare each
pixel of each image and calculate the significance of the differ-
ence for each.  These results can then be represented as signifi-
cant differences, which are colour coded P < 0.001 red, P < 0.01
orange, P < 0.05 green, P > 0.05 < 0.1 in blue. By applying change
detection analysis to monoclonal antibody imaging in this way, typ-
ically 90% of involved but impalpable axillary nodes can be detect-
ed [1–3]. This enables a strategy to be developed (Table 2). If pal-
pation and cytology are positive in the axilla then axillary clear-
ance is undertaken, but if no lymph node is palpable then imag-
ing is performed. If the image is positive then there is axillary clear-
ance, but if the imaging is negative then a Sentinel Node study is
performed. If the Sentinel node is positive on histology, there is
axillary clearance whereas if the Sentinel node is negative on his-
tology no axillary clearance is performed. This assessment means
that axillary clearance is not performed unless the triple evalua-
tion is negative.  It is also a problem with Sentinel Nodes that false
negatives may occur if a lymph node is totally replaced with can-
cer cells, such nodes are the easiest for the imaging technique to
find, hence the importance of combining the two modalities.
Prostate cancer
The clinical questions are:
1. What is the extent of prostate cancer when radical surgery or
radioactive implant seeds are proposed at treatment?
Table 2. Strategy for axillary nodes in breast cancer
Palpation and Cytology Positive: Axillary Clearance
Palpation Negative: Image Axilla
Imaging Positive: Axillary Clearance
Imaging Negative: Sentinel Node study
Sentinel Node Positive Histology: Axillary Clearance
Sentinel Node Negative Histology: No Axillary Clearance
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terisation is an optimised binder, which has high density on the
cell, homogeneity of expression between the cells, as specific as
possible and independent of the grade of the cancer. The proper-
ties of the bindee should be of high avidity, small with stable la-
belling, as specific as possible and having renal excretion rather
than gut excretion.  To use a receptor binding radionuclide ligand
for imaging or therapy it is required to know which tumours have
which receptors and which radionuclide ligands bind to which re-
ceptors. Therefore prior imaging with the same radionuclide ligand
is required before radionuclide therapy. Thus one can obtain
a prediction of a therapeutic response before initiating therapy,
an important concept in oncology.
Indium-111 Octreotide in gastro-endocrine tumours appears
to be cost beneficial in patients with carcinoid, para-ganglioma
and gastrinoma, but less so in medullary thyroid carcinoma and
insulinoma [8]. Alternative peptides include I-123 labelled vaso
active intestinal peptide, a stimulatory peptide [9]. Radiolabelled
alpha-melanocyte stimulating hormone for melanoma, Cholecys-
tokinin for gastrointestinal cancers and Bombesin for Lung can-
cer, are being evaluated. Interleukin 2 has been labelled with
Tc-99m or I-123 [10]. This binds to activated T cells which sur-
round the melanoma. For example melanoma therapy with Inter-
leukin 2 may be confined to those melanomas that show good
uptake of Interleukin 2 labelled with Tc-99m [11]. In fact in Oncol-
ogy infusions of various Cytokines for cancer therapy are used
increasingly. Some patients respond and some do not. Is it not
time for evidence of uptake in the tumour environment to be ob-
tained using a radiolabelled Cytokine to predict efficacy before
expensive and maybe ineffective treatment is undertaken?
Tc-99m Depreotide is a good peptide for imaging lung can-
cer and some neuro-endocrine tumours [12].
Radionuclide imaging and therapy
The advantage of radionuclide therapy over chemotherapy in
cancer is that one is able to find and treat the individual. Most
cancer surgery and radiotherapy is based on the physical extent
of the disease and not the biological extent. Most cancer chemo-
therapy is based on the clinical trials of the many and may or may
not work in the individual. For example if 30% of patients respond
to a particular chemotherapy it means that 70% have side effects
and no therapeutic benefit. Radiolabelling and imaging of che-
motherapy agents may be an answer to this problem. In Nuclear
Medicine it is answered by having an imaging radionuclide that is
gamma emitting and this gamma emitting radionuclide is then
substituted with a therapy radionuclide, which may be beta or al-
pha emitting on the same agent. In this way only those patients
are exposed to radiation therapy that have demonstrated by im-
aging significant and specific tumour uptake. Those patients that
do not demonstrate this should not receive radionuclide therapy.
Thus thyroid cancer should not be treated with I-131 therapy un-
less there has been evidence previously obtained of iodine avidity
of the cancer [13]. The various agents are summarised in Table 3.
For neuro-endocrine tumours one can fallow this imaging strate-
gy (Table 3). Unfortunately, the availability of Y-90 Octreother is
dependent on the outcome of a multicentred trial and the avail-
ability of Y-90 Lanreotide therapy is also uncertain. It is possible to
image the Bremstrahlung radiation from the Y-90 and show that it
confirms location of the therapy with the Indium-111 Octreotide
image positive sites.
A new approach developed by DeChristoforo et al. [14, 15]
has been the development of Tc-99m EDDA-HYNIC-TOC. They
have shown that 140 patients who were Indium-Octreotide avid
showed uptake of the Technetium 99m Octreotide «Tectoc» equal
to or greater than that of the Indium-111 Octeotide. They also
showed new sites with the Technetium agent in 10% of patients.
This agent then opens the possibility of substituting Tc-99m with
Re-188 Beta emitter (Half Life 17 hours 2.2 MeV, 11 mm range) as
a radionuclide therapy.
Conclusions
1. This type of imaging depends on identifying differences be-
tween the cancer cell and the normal cell.
2. This imaging identifies sheets, ribbons, plaques and infiltration
of Cancer that cannot be identified radiologically because of their
lack of mass. There are implications for radiotherapy planning.
3. This imaging is positive in dormant cancer cells.
4. Cancer imaging prior to radionuclide therapy excludes those
patients who will not respond (unlike chemotherapy) and those
who will take up the therapy agent and are likely to respond.
5. The Cancer imaging and therapy will progress as genetically
engineered and synthetic molecules mimicking the proper-
ties of monoclonal antibodies and peptides become avail-
able. This will help to overcome regulatory problems. The
future is bright.
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